CDK4 and cancer: CDK4 complexed with cyclin D isoforms, constitutes an established pharmacological target in several human cancers, associated with mutation of CDK4, amplification of cyclin D or overexpression of p16INK4a, all of which lead to hyperactivation of this kinase.